The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals.
George Zogopoulos, Ido Haimi, Shenin A Sanoba...
https://pubmed.ncbi.nlm.nih.gov/38626807/Actively Recruiting
Age: 18Years - 90Years
All Genders
Healthy Volunteers
ID04970056
Pancreatic Cancer Early Detection Consortium Observational Study of High-Risk Individuals and Pancreatic Conditions
Led by Arbor Research Collaborative for Health · Updated on 2026-07-22
20000
Participants Needed
60
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying pancreatic ductal adenocarcinoma PDAC by establishing a large group of people at high risk due to family history or genetic variants. The goal is to improve early detection and prevention of PDAC through detailed research on these individuals over time. This observational study collects blood and other biosamples every 6 to 12 months from participants in defined high-risk groups. Standardized procedures are used for sample collection and processing, and samples are stored at clinical sites with linked patient data. Participants receive usual medical care from their doctors while contributing samples and clinical information. Participants provide biosamples and information during follow-up visits, with clinical data obtained from medical records. Researchers track the development of PDAC over an average of six years. The study measures include monitoring for PDAC development and correlating clinical outcomes with laboratory results from biospecimens. This long-term follow-up helps advance understanding of PDAC risk and detection.
CONDITIONS
Brief Title
Pancreatic Cancer Early Detection Consortium
Research Team
N
Naveen Fawas, BS
J
John Graff, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here